Qing jing Hu

Qing jing Hu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
JZJiale Zhang
Jiale Zhang
HTHongxuan Tong
Hongxuan Tong
LJLijie Jiang
Lijie Jiang
YZYiwen Zhang
Yiwen Zhang
QHQing jing Hu
Qing jing Hu

15 June 2023 in Annals of Medicine
Verified
Journal Article
Open access
JZJiaxi Zou
Jiaxi Zou
WXWeiming Xu
Weiming Xu
ZLZiyun Li
Ziyun Li
PGPing Gao
Ping Gao
FZFangyuan Zhang
Fangyuan Zhang
QHQing jing Hu
Qing jing Hu
Si-Miao-Yong-An decoction (SMYAD) is a conventional therapeutic formula for treat thromboangiitis obliterans (TAO), consisting of four Chinese herbs: Lonicerae japonicae Thunb. (Jinyinhua), Scrophularia ningpoensis Hemsl. (Xuanshen), Angelica sinensis (Oliv.) Diels (Danggui) and Glycyrrhiza uralensis Fisch. (Gancao). However, the mechanism of SMYAD in TAO treatment remains unclear. Components, as well as potential targets of SMYAD in TAO therapy, were downloaded from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Subsequently, with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) server, the gene ontology (GO) biological processes and the Kyoto encyclopedia of genes and genomes (KEGG) signalling pathways of the targets enrichment were performed. Next, based on STRING online database, the protein interaction network of vital targets was built and analysed. Molecular docking and calculation of the binding affinity were performed using AutoDock. The PyMOL software was employed to observe docking outcomes of active compounds and protein targets. Based on the predicted outcomes of network pharmacology, in vivo and in vitro tests were performed for validation. In vivo experiment, the TAO rats model was established using sodium laurate injection into the femoral artery. The symptoms as well as pathological changes of the femoral artery were observed. Besides, the predicted targets were verified by the RT-qPCR, in vitro experiment. The cell viability in LPS-induced human umbilical vein endothelial cells (HUVECs) was detected using CCK-8 kit, and the predicted targets were also verified by the RT-qPCR. In the network pharmacology analysis, we obtained 105 chemical components in SMYAD and 24 therapeutic targets. We found that the mechanism SMYAD in TAO therapy was primarily associated with inflammation and angiogenesis by constructing multiple networks. Quercetin, vestitol and beta-sitosterol were important compounds, and interleukin-6 (IL6), MMP9, and VEGFA were key targets. According to molecular docking, active compounds (quercetin, vestitol and beta-sitosterol) and targets (IL6, MMP9 and VEGFA) showed good binding interactions. In in vivo experiment, SMYAD ameliorated the physical signs and pathological changes, inhibited the expression of IL6 and MMP9, and enhanced the expression of VEGFA. In an in vitro experiment, SMYAD increased the cell viability of LPS-induced HUVECs and the expression of VEGFA, and reduced the expression of IL6 and MMP9. This study showed that SMYAD improves TAO symptoms and inhibits the development of TAO. The mechanism could be associated with anti-inflammatory and therapeutic angiogenesis.

29 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WNWenyi Nie
Wenyi Nie
YYYingbin Yue
Yingbin Yue
QHQing jing Hu
Qing jing Hu
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), and neuroinflammation. Monocytes and macrophages, particularly microglia, play a dual role in AD pathogenesis. In the early stages, they delay disease progression by phagocytosing Aβ, but chronic activation leads to Aβ accumulation and exacerbated neuroinflammation. Monocyte chemoattractant protein 1 (MCP-1) is a key regulator in neuroinflammation, Aβ deposition, and tau pathology, making it a potential therapeutic target. Moreover, recent breakthroughs in fluid and imaging biomarkers and targeted immunomodulatory agents underscore the growing importance of early diagnostic and therapeutic interventions. This review explores the complex interplay between monocytes, macrophages, and AD pathology, highlighting their roles in neuroinflammation, Aβ metabolism, and tau phosphorylation. Understanding these mechanisms offers new insights into developing effective diagnostic biomarkers and therapeutic strategies for AD.

18 March 2025 in Brain and Behavior
Verified
Journal Article
Open access
WNWenyi Nie
Wenyi Nie
QHQing jing Hu
Qing jing Hu
Background: Prior research has consistently shown an association between muscle strength and various metabolic diseases. However, the relationship between muscle strength and cognitive impairment remains elusive.Methods: Using data from the 2011–2014 National Health and Nutrition Examination Survey (NHANES), we investigated the association between muscle strength and cognitive impairment. We used multivariate logistic regression, restricted cubic spline regression (RCS), and threshold effects to investigate the impact of muscle strength on cognitive function. In addition, we analyzed the correlation between muscle strength and cognitive impairment in subgroups of age, gender, race, education, smoking status, drinking status, hypertension, diabetes, and heart disease.Results: 2124 participants were ultimately included for further analysis. Multivariate logistic regression, trend testing, and RCS analysis showed a non‐linear negative correlation between muscle strength and cognitive impairment. Threshold effect analysis suggests that when muscle strength reaches a certain value, this relationship undergoes significant changes. In the three cognitive function scoring tests, interaction was only observed in the racial subgroup.Conclusion: This study suggests a negative correlation between muscle strength and cognitive function, which may have a threshold effect. Further longitudinal studies are needed to elucidate its potential mechanisms.

1 January 2024 in American Journal of Translational Research
Verified
Journal Article
Closed access
YZYue Zhao
Yue Zhao
JZJiale Zhang
Jiale Zhang
FLFei Lu
Fei Lu
WXWeiming Xu
Weiming Xu
QMQingxiao Ma
Qingxiao Ma
QHQing jing Hu
Qing jing Hu
Honeysuckle is a conventional Chinese medicine with several therapeutic applications. With the advancement of modern scientific technologies, Honeysuckle’s pharmacological effects and medicinal properties have been investigated more thoroughly. Studies demonstrate that the bioactive compounds in Honeysuckle possess anti-inflammatory effects via several mechanisms, protecting the cardiovascular system. This article provides a reference for the clinical use of Honeysuckle by reviewing research on the therapeutic impact of Honeysuckle and its active constituents on cardiovascular diseases, such as coronary atherosclerotic heart disease (CHD), myocardial ischemia-reperfusion (MI/R), acute myocardial infarction (AMI), hypertension, arrhythmia, and heart failure, through the inhibition of inflammatory responses.

19 October 2024 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
YCYuting Cui
Yuting Cui
ZLZiyun Li
Ziyun Li
PGPing Gao
Ping Gao
WXWeiming Xu
Weiming Xu
QHQing jing Hu
Qing jing Hu
Background: Dyslipidemia is considered a substantial risk factor for coronary heart disease (CHD). Blood lipid levels in patients with CHD influence cardiovascular events. Therefore, it is critical to monitor and control these levels. As a traditional, complementary alternative therapy, acupuncture regulates blood lipid levels in patients with CHD. More acupuncture-related treatments are currently available. However, systematic reviews or evidence-based summaries have yet to be conducted. Methods: This study included a randomized controlled trial of the effects of acupuncture-related therapies on blood lipid levels in CHD patients. The outcome indicators were changes in the TC, TG, LDL-C, and HDL-C levels. Two independent reviewers extracted data from PubMed, Web of Science, EMBASE, Cochrane Library, Medline (Ovid), China Knowledge Network, Wanfang, Vipshop, and SinoMed databases until January 7 2024. The literature quality was assessed using RevMan 5.4.1. The data were analyzed using the Frequentist network metaanalysis with STATA 15.1 software. Network meta-analysis was used to compare direct and indirect evidence, and a cumulative ranking curve (SUCRA) was used to evaluate the curative effect. For consistency, global inconsistency and ring-inconsistency test evaluations were used. The Cochrane bias risk assessment tool was used to assess quality. Results: Fourteen studies with 1416 patients were included in the study. The evidence network shows that there are many studies on acupuncture and warm acupuncture. According to the direct comparison and SUCRA ranking, acupuncture reduced TC [- 1.82 (- 3.36, - 0.28)], heat-sensitized moxibustion lowered TG [- 2.12 (3.55, - 0.69)], LDL-C [- 1.37 (- 2.09, - 0.66)], and increased HDL-C [0.87 (0.52, 1.22)]. These two interventions were the first in the SUCRA ranking. The inconsistency analysis revealed that direct evidence corresponded with indirect evidence. There were some methodological defects in the included studies, and some studies did not implement blinding methods, had small sample sizes or other problems. Conclusions: Heat-sensitized moxibustion significantly lowered TG and LDL-C levels and elevated HDL-C levels. Acupuncture significantly reduced TC levels. Heat-sensitized moxibustion is a more effective intervention than other acupuncture-related treatments for regulating blood lipid levels in patients with CHD. However, this study has several limitations, and clinical practice should be performed as needed.